SeekingAlpha · Nov 18, 2026
Novo Nordisk: The Worst May Be Behind
Novo Nordisk is rated a long-term Buy, as falling capital spending supports higher free cash flow, with a DKK 393.21 intrinsic value.
NYSE · NVO
Healthcare · Drug Manufacturers - General
$38.87
Down-$0.54 (-1.38%)
Updated Nov 20, 2026, 5:52 PM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · NVO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
NVO closed at $38.87 after 21 trading sessions, down 1.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $39.355 | $39.815 | $38.61 | $38.87 | 17.73M |
| Nov 18, 2026 | $40.135 | $40.57 | $39.32 | $39.43 | 16.57M |
| Nov 17, 2026 | $40.715 | $40.96 | $40.23 | $40.70 | 17.84M |
| Nov 16, 2026 | $42.05 | $42.30 | $41.44 | $41.60 | 16.66M |
| Nov 13, 2026 | $40.97 | $41.80 | $40.6395 | $41.63 | 11.71M |
| Nov 12, 2026 | $40.93 | $41.01 | $40.08 | $40.65 | 15.75M |
| Nov 11, 2026 | $40.50 | $41.20 | $40.095 | $41.09 | 11.71M |
| Nov 10, 2026 | $40.71 | $40.8061 | $40.38 | $40.70 | 6.53M |
| Nov 9, 2026 | $41.135 | $41.63 | $40.55 | $41.38 | 11.76M |
| Nov 6, 2026 | $39.76 | $40.55 | $39.5347 | $40.31 | 9.24M |
| Nov 5, 2026 | $41.155 | $41.175 | $39.99 | $40.30 | 18.5M |
| Nov 4, 2026 | $42.45 | $43.24 | $42.12 | $42.18 | 26.04M |
| Nov 3, 2026 | $40.34 | $40.6343 | $39.96 | $40.19 | 12.22M |
| Nov 2, 2026 | $40.10 | $40.78 | $40.06 | $40.45 | 11.18M |
| Oct 30, 2026 | $39.61 | $40.10 | $39.54 | $40.00 | 15.28M |
| Oct 29, 2026 | $38.67 | $39.22 | $38.56 | $39.14 | 10.44M |
| Oct 28, 2026 | $38.11 | $38.54 | $37.96 | $38.29 | 11.36M |
| Oct 27, 2026 | $38.58 | $39.025 | $38.54 | $38.67 | 6.78M |
| Oct 26, 2026 | $39.02 | $39.235 | $38.67 | $39.13 | 8.04M |
| Oct 23, 2026 | $39.21 | $39.29 | $38.75 | $39.05 | 9.19M |
| Oct 22, 2026 | $39.39 | $39.765 | $39.24 | $39.43 | 8.56M |
The latest Smart Investors Daily articles mentioning NVO.
Company
Market Activity
Research & News
NVO research
Company profile and research snapshot.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 23, 2026 | JYSKE BANK | Hold | — |
| Sep 22, 2026 | BANCO SANTANDER | Outperform | — |
| Sep 22, 2026 | DNB CARNEGIE | Buy | — |
| Sep 22, 2026 | TD COWEN | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Nov 18, 2026
Novo Nordisk is rated a long-term Buy, as falling capital spending supports higher free cash flow, with a DKK 393.21 intrinsic value.
Yahoo · Nov 18, 2026
nference today announced a strategic collaboration with Novo Nordisk (Novo) to advance research in cardiometabolic disease, including conditions such as obesity, diabetes, and cardiovascular disease.
Yahoo · Nov 18, 2026
Novo Nordisk has seen its share price fall 57.9% over the past three years, even as its weight loss franchise remains central to the investment story. That slump now puts a sharper focus on whether the current price around US$40.70 can still be explained by the earnings power investors are paying for. The 57.9% decline over three years raises the question of how much of Novo Nordisk's earlier optimism has been stripped out of the valuation. Recent updates around Wegovy and the potential...
Yahoo · Nov 18, 2026
Novo Nordisk (NYSE:NVO) is back in focus after its collaboration with Anthropic was highlighted as a driver of AI assisted drug discovery and software development. Investors are weighing what this partnership implies for long term R&D productivity. Novo Nordisk’s AI push with Anthropic is landing at a tricky moment for the ticker, with the share price at US$40.70 and short term momentum mixed. The stock has risen over the past month but is still down double digits year to date, and the 1 year...
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S shares currently trade at $39.43, reflecting a notable 5.93% gain over the past month but remaining under pressure on longer time horizons. Per SID market data, the stock has declined 12.44% over the trailing three months and 15.67% over the past year, underperforming the broader healthcare sector. The 14-day relative strength index stands at 61.2, indicating momentum approaching but not yet reaching overbought territory. NVO trades slightly below its 50-day moving average of $39.90 and materially below its 200-day moving average of $43.00, signaling a persistent longer-term downtrend despite the recent monthly rebound. According to Massive/Polygon data, average daily trading volume is approximately 16.7 million shares, reflecting sustained institutional interest. The stock's beta of 0.352 indicates significantly lower volatility relative to the broader market, consistent with its defensive healthcare positioning. The company's market capitalization stands at approximately $223.5 billion.
Novo Nordisk A/S trades at a price-to-earnings ratio of 12.76, according to SID market data, a level that appears compressed relative to the company's historical premium as a dominant GLP-1 franchise leader in the healthcare sector. The PEG ratio stands at 2.05, suggesting the stock is priced above a one-to-one earnings growth parity, which indicates the market may be pricing in some growth deceleration risk. Per SEC filings, the price-to-book ratio is 8.43, reflecting substantial intangible value embedded in the company's insulin and obesity drug portfolio. Novo Nordisk offers a dividend yield of 3.66%, providing meaningful income for shareholders at current price levels. The combination of a sub-13 P/E with a nearly 4% yield represents a valuation profile that diverges significantly from its recent years when the stock commanded substantially higher earnings multiples amid peak GLP-1 enthusiasm across the pharmaceutical landscape.
Novo Nordisk A/S registers a composite smart money score of 53 out of 100, per SID market data, reflecting a neutral overall signal from sophisticated market participants. Institutional activity represents the strongest component, scoring 23.0 out of 25, indicating robust positioning from major fund managers and asset allocators. According to SEC Form 4 filings, insider activity scores 12.5 out of 25, suggesting moderate but not aggressive buying or selling among company executives and directors. Congressional trading activity scores 10.4 out of 25, reflecting limited but present legislative interest in the stock. Dark pool activity registers the weakest score at 7.6 out of 25, per 13F institutional filings, indicating below-average off-exchange block trading volume relative to peers. The divergence between strong institutional ownership signals and muted dark pool activity suggests that large holders are maintaining existing positions rather than actively accumulating or distributing shares at current price levels. The neutral composite reading aligns with the stock's recent sideways consolidation pattern.
Novo Nordisk A/S delivered an earnings surprise in its most recent reported quarter, posting actual earnings per share of $0.89 versus the consensus estimate of $0.81, representing a positive surprise of $0.08 or approximately 9.9%, according to company earnings reports. This beat demonstrates continued operational execution despite broader concerns around competitive dynamics in the GLP-1 market. Per analyst estimates, the consensus expectation for the next three upcoming quarters is $0.81 per share in each period, suggesting Wall Street anticipates stable but flat sequential earnings trajectory. The uniform estimate across quarters indicates analysts may be awaiting additional guidance before differentiating seasonal or pipeline-driven variations. The next earnings report is scheduled for August 21, 2026. Investors will be monitoring whether the company can sustain its pattern of exceeding estimates, particularly as competitive pressures from rival obesity and diabetes treatments continue to intensify across the pharmaceutical industry.
Recent Wall Street analyst activity on Novo Nordisk A/S reflects a split but generally constructive outlook. Per SID consensus data, Rothschild & Co Redburn reiterated a Buy rating on September 23, 2026, while DNB Carnegie maintained its Buy recommendation on September 22, 2026, underscoring continued confidence from European-focused research houses. Banco Santander also reiterated an Outperform rating on September 22, 2026, according to Wall Street analyst reports. Counterbalancing the bullish calls, Jyske Bank maintained its Hold rating on September 23, and TD Cowen reiterated Hold on September 22, reflecting caution among certain analysts regarding near-term catalysts. Notably, all five recent ratings represent reiterations rather than upgrades or downgrades, indicating that the recent 5.93% monthly rally has not prompted meaningful shifts in analyst conviction. The absence of any Sell ratings among recent coverage actions suggests that the analyst community views the current valuation as offering limited downside risk at $39.43 per share.


The latest Smart Investors Daily articles mentioning NVO.